DAILYPEPTIDE GUIDE
Experimental / RUO

MOTS-c

Mitochondrial open reading frame of 12S rRNA-c

MOTS-c is cataloged for research literacy, with a clear separation between proposed mechanisms, marketed claims and validated human evidence.

Compare
EvidenceTier 3
RegulatoryUnapproved / RUO
SafetyUncertain or Concerning
Clinical phaseRUO
01

Overview

ClassMitochondrial-derived peptide
Sponsor / developerNo approved-product sponsor
Review statusReviewed
Record IDPEP-040
02

Plain-language guide

What it was designed or studied for

Discussed or marketed in research-only contexts for Longevity claims, Exercise claims, Metabolic research. It is not approved for treating these uses.

How it works, simply

It is intended to affect mitochondria—the parts of cells that manage energy. That mechanism does not automatically translate into better exercise or recovery.

This simplified explanation is educational context, not a treatment recommendation or a substitute for the clinical evidence below.
03

Clinical mechanism

Metabolic and mitochondrial mechanisms are primarily preclinical.

Mechanism plausibility is not the same as demonstrated clinical benefit.
04

Applications

  • Longevity claims
  • Exercise claims
  • Metabolic research
05

Human evidence

Validated human efficacy evidence is absent, limited or not independently replicated.

Tier 3
06

Preclinical evidence

Mechanistic and preclinical findings are tracked separately and are not treated as proof of human clinical benefit.

MAP

Muscle & recovery profile

Each signal is scored independently from 0–5. There is no composite “best” score.

Growth relevance1/5
Preservation relevance2/5
Recovery relevance2/5
Mitochondrial support4/5
Connective tissue0/5
Human-data depth0/5
Safety confidence0/5
Evidence–hype gap5/5

Evidence classes

  • Preclinical animal evidence
  • Laboratory / in-vitro evidence
  • Anecdotal report
  • Marketing claim

What has been studied

  • Preclinical work explores metabolism, exercise adaptation and mitochondrial signaling.

What is not established

  • Human efficacy, dose, product identity, long-term safety and clinical benefit are not established.

Studied populations

  • Preclinical models

Major limitations

  • Muscle-specific outcomes may be secondary, exploratory or absent from available studies.
  • Findings from one population, formulation or indication should not be generalized to another.

Evidence-source categories: primary regulatory record, clinical trial registry, peer reviewed literature. These editorial source categories require record-level primary links before publication-grade citation export.

06

Regulatory status

Unapproved / RUO. Regulatory status is product- and jurisdiction-specific and does not automatically follow from an evidence score.

07

Safety

Uncertain or Concerning

  • Human safety data are incomplete
  • Product identity, sterility and dose consistency may be unknown
08

Interactions

Combination data are sparse. Absence of documented interaction evidence is not evidence of compatibility.

09

Treatment pattern

No validated human dosing or cycling protocol exists.

10

Manufacturing and quality

RUO and grey-market products may not establish identity, net content, sterility, endotoxin control or cold-chain integrity.

12

Sources

  1. 01
    Primary regulatory record

    Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.

  2. 02
    Clinical trial registry

    Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.

  3. 03
    Peer-reviewed literature

    Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.

13

Gaps and unverified claims

  • No validated human dosing or cycling protocol exists.
  • Long-term safety and product-quality consistency remain unresolved.
14

Last reviewed

August 5, 2026 · Reviewed